Flow Neuroscience is aiming to change how we treat depression. The start-up has developed a non-invasive, medication-free personal medical device that can not only address depression physically in the brain, but can also collect data through an app to further increase our knowledge of the disease and its causes. Using a headset, Flow Neuroscience sends a TDCS (Transcranial Direct-Current Stimulation), or very weak current, through a person’s head. This current affects the neurons in the brain, making them become a little bit more active on the left side and a little less active on the right side of the head. This has been proven to reduce the effect of depression by about 30-35%.


There are two ways of commonly treating depression today: antidepressants – which is by far the most common – and therapeutics. Antidepressants can have side effects, some of which can be quite severe, whilst therapeutics is not scalable, as some people don’t want to reach out to a psychologist. Flow Neuroscience is building something that can be delivered to as many people as possible, quickly and easily, without any side effects.


More than 300 million people suffer from depression globally, according to the World Health Organisation.


The company has raised a $1.1m Seed round, with investors including Khosla Ventures and SOSV. Flow Neuroscience also took part in the HAX 2017 accelerator program in the US.